Sight Sciences (Sight Sciences) Interest Expense : $-5.34 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Sight Sciences Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sight Sciences's interest expense for the three months ended in Mar. 2024 was $ -1.20 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-5.34 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Sight Sciences's Operating Income for the three months ended in Mar. 2024 was $ -14.72 Mil. Sight Sciences's Interest Expense for the three months ended in Mar. 2024 was $ -1.20 Mil. Sight Sciences did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sight Sciences Interest Expense Historical Data

The historical data trend for Sight Sciences's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sight Sciences Interest Expense Chart

Sight Sciences Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-1.96

-2.40

-4.37

-4.47

-5.41

Sight Sciences Quarterly Data
	Dec18	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial														-1.28	-1.35	-1.43	-1.35	-1.20

Sight Sciences Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.34 Mil.

Sight Sciences (NAS:SGHT) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sight Sciences's Interest Expense for the three months ended in Mar. 2024 was $-1.20 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-14.72 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $34.50 Mil.

Sight Sciences's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Sight Sciences did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Sight Sciences (Sight Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sight Sciences Inc (NAS:SGHT) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

4040 Campbell Avenue, Suite 100, Menlo Park, CA, USA, 94025

Website

https://www.sightsciences.com

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.

Executives

Jeremy B. Hayden	officer: Chief Legal Officer	2 MUSICK, 2 MUSICK, IRVINE CA 92618
Sam Boong Park	officer: Chief Operating Officer	C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
Paul Badawi	director, 10 percent owner, officer: President and CEO	C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
David Badawi	director, officer: Chief Technology Officer	C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
D1 Capital Partners L.p.	10 percent owner	9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019
Staffan Encrantz	director	C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
Matthew Link	officer: Chief Commercial Officer	7475 LUSK BLVD, SAN DIEGO CA 92121
Catherine Mazzacco	director	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Alison Bauerlein	officer: See remarks	326 BOLLAY DRIVE, GOLETA CA 93117
James Rodberg	officer: See Remarks	C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVE., SUITE 100, MENLO PARK CA 94025
Tamara Fountain	director	C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Brenda Jane Larsen-becker	director	C/O SIGHT SCIENCES, INC., 3000 SAND HILL ROAD, BUILDING 3, STE 105, MENLO PARK CA 94025
Jesse Selnick	officer: Chief Financial Officer	C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
Daniel S. Sundheim	10 percent owner	C/O D1 CAPITAL PARTNERS L.P., 9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019
Erica J. Rogers	director	C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089